Determining ultratrace amounts of protein biomarkers in patient samples in a straightforward and quantitative manner is extremely important for early disease diagnosis and treatment. Here, we successfully demonstrate the novel use of zinc oxide nanorods (ZnO NRs) in the ultrasensitive and quantitative detection of two acute kidney injury (AKI)-related protein biomarkers, tumor necrosis factor (TNF)-α and interleukin (IL)-8, directly from patient samples. We first validate the ZnO NRsbased IL-8 results via comparison with those obtained from using a conventional enzyme-linked immunosorbent method in samples from 38 individuals. We further assess the full detection capability of the ZnO NRs-based technique by quantifying TNF-α, whose levels in human urine are often below the detection limits of conventional methods. Using the ZnO NR platforms, we determine the TNFα concentrations of all 46 patient samples tested, down to the fg/mL level. Subsequently, we screen for TNF-α levels in approximately 50 additional samples collected from different patient groups in order to demonstrate a potential use of the ZnO NRs-based assay in assessing cytokine levels useful for further clinical monitoring. Our research efforts demonstrate that ZnO NRs can be straightforwardly employed in the rapid, ultrasensitive, quantitative, and simultaneous detection of multiple AKI-related biomarkers directly in patient urine samples, providing an unparalleled detection capability beyond those of conventional analysis methods. Additional key advantages of the ZnO NRs-based approach include a fast detection speed, low-volume assay condition, multiplexing ability, and easy automation/integration capability to existing fluorescence instrumentation. Therefore, we anticipate that our ZnO NRs-based detection method will be highly beneficial for overcoming the frequent challenges in early biomarker development and treatment assessment, pertaining to the facile and ultrasensitive quantification of hardto-trace biomolecules.
Introduction
Cytokines and a subgroup of chemoattractant cytokines known as chemokines are signaling proteins produced by many cells such as neutrophils, monocytes, macrophages, and T-cells. [1] [2] [3] [4] [5] Cytokines and chemokines regulate immune responses and are known as important biomarkers of inflammatory diseases. Hence, they are widely used to track and predict disease progressions as well as to monitor patient treatment outcomes. [6] [7] [8] [9] One such example is acute kidney injury (AKI), a common disorder with high morbidity and mortality rates in the hospital setting whose biomarkers include various cytokines and chemokines such as interleukins (ILs) and tumor necrosis factors (TNFs). [8] [9] [10] [11] [12] The potentially decisive diagnostic importance of cytokine and chemokine biomarkers continues to drive new assay development. [13] [14] [15] The most common methods of detecting cytokines rely on enzymelinked immunosorbent assays (ELISAs). 3, 16, 17 Yet, such traditional diagnostic procedures widely employed for the measurement of biomarkers tend to require long assay times and extensive workflows.
In addition, these standard methods are often limited to measuring a single type of protein per run.
Moreover, typical detection sensitivities of conventional ELISA assays may be insufficient to discern biologically significant perturbations in weakly expressed cytokines. To overcome these challenges, approaches such as microsphere-based assays 18, 19 and polymerase chain reaction (PCR)-based assays 20, 21 have been developed. For example, previous studies have used bioluminescent proteins as alternative labeling sources to reduce autofluorescence and to permit IL-6 and IL-8 detection in the low pg/mL range. 22 Immuno-PCR methods, generally employing single DNA-coupled antibodies whose signals are amplified with additional steps such as rolling cycle amplification, have yielded a detection range of less than 10 pg/mL for many cytokines. 23 Electroluminescence and square-wave voltammetry methods have also been used to measure TNF-α levels in the range of 3~7 pg/mL. 24 Surface plasmon resonance (SPR) and local surface plasmon resonance (LSPR) effects have been more recently exploited for cytokine measurements as well. The lowest concentration levels of IL-1β and TNF-α in physiologically relevant samples tested with a SPR-based sensor have been reported to be in the 1 ng/mL range 25 and further improved to ~50 pg/mL with the addition of Au nanoparticles for signal Page 3 of 29 Nanoscale Nanoscale Accepted Manuscript 4 amplification. 26 An optical fiber sensor coupled with Au nanoparticles for LSPR can detect IL-1β of concentrations as low as several tens of pg/mL. 27 These and the wealth of other studies in the literature underscore the significance of cytokines and chemokines in both basic biological and biomedical research as well as the high demand for achieving ultrasensitive detection limits (DLs) of these biomarker proteins in more applied clinical contexts.
The levels of disease-implicated cytokines and chemokines in humans are often well below the tens of pg/mL range which is the customary DLs of conventional techniques. Accordingly, there is a great interest in reducing the lower limits of detection down to the fg/mL range. In particular, the evergrowing need for early diagnosis and treatment in AKI and other cytokine-implicated diseases further warrants an innovative detection means capable of reaching even lower DLs than those currently offered. In this context, we have shown that ZnO NRs permit enhanced detection of fluorescence signals emitted by biomolecules in the form of custom-prepared oligonucleotide constructs and highly purified single-composition proteins in simple media. [28] [29] [30] [31] [32] [33] In this study, we quantify TNF-α and IL-8, two AKI-related biomarkers, in urine samples obtained from patients at risk for AKI by using ZnO NR platforms in fluorescence-based assays. We demonstrate that ultralow amounts of the biomarker proteins can be quantified rapidly and simultaneously in biologically complex, clinical samples using the newly developed ZnO NR fluorescence assay platform. Furthermore, we compare the biomarker readings determined using the ZnO NR platform with the results obtained using a conventional ELISA-based assay on the same patient samples. We determine that the ZnO NR platform can quantify TNF-α and IL-8 levels in urine down to the concentration range of several fg/mL. Lastly, we assess the feasibility of our ZnO NRs-based approach to distinguish between different patient groups to serve as a guide in clinical monitoring. Our efforts presented in this study verify that the exquisite levels of detection for urine cytokines can be conveniently and straightforwardly achieved from minimally processed patient samples, well beyond the detection limits of other standard techniques. Hence, exciting future applications of the ZnO NRs-
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Experimental Methods
ZnO NR Platform Synthesis. The ZnO NR platforms employed for the chemokine and cytokine assays were fabricated by synthesizing vertically oriented ZnO NRs atop a Si substrate in a preconfigured square array pattern. A gas phase synthesis was performed in a home-built chemical vapor deposition reactor, similar to the previously described procedures. [28] [29] [30] [31] [34] [35] [36] [37] [38] [39] Briefly, the Si substrate was prepatterned by microcontact printing 20 nm Au colloidal catalysts (Ted Pella, Inc.; Redding, CA) using an elastomeric poly(dimethylsiloxane) stamp containing periodic square features with side lengths of 10 µm. Subsequent growth of ZnO NRs was carried out by heating a 2:1 by weight mixture of zinc oxide (99.999% purity; Alfa Aesar Inc.) and graphite (99.99% purity; Alfa Aesar, Inc) to 950 °C for 1 h under a constant Ar gas flow.
Preparation of the Proteins and Antibodies. Unlabeled monoclonal anti-human IL-8 (clone 6217, R&D Systems) and TNF-α (clone 6401, R&D Systems) antibodies were used as the primary capture antibodies in the duplexed sandwich assay. Recombinant human IL-8 and TNF-α (R&D Systems), were reconstituted in deionized water (DI) to a concentration of 2 ng/mL and 10 ng/mL, respectively, and stored in small aliquots at -70 °C until use. IL-8 and TNF-α calibration standards were prepared fresh each assay day by serial dilution of the human IL-8 and TNF-α to the following concentrations: 
Results and Discussion
TNF-α and IL-8 were selected as model cytokines and chemokines in our study due to their pertinence in the pathophysiology and diagnosis of AKI as well as their typical concentration levels found in urine.
The relevance of the TNF-α and IL-8 markers to AKI has been reported in the past. [6] [7] [8] [9] In addition to their biomedical relevance, the differences in the typical ranges of TNF-α and IL-8 in urine samples make them ideal to evaluate our ZnO NRs-based detection approach. The typical concentration levels of TNF-α in human urine samples are often below the DLs of conventional cytokine detection platforms. 41 Those of IL-8, on the other hand, typically exhibit values above several tens of pg/mL and well into the ng/mL range, 42, 43 which can be determined with traditional techniques. Therefore, we carried out both ELISA-and ZnO NRs-based assays from the same set of patient samples. By performing the two comparative assays of the ELISA-and ZnO NRs-based detection on the same set of patient samples, we first examined whether the IL-8 levels from the highly-expressed samples agree between the two detection methods. Next, we assessed the detection capability of the ZnO NRs in ascertaining those ultralow protein levels of TNF-α in the patient samples that fall below the ELISA DL. The assay method is outlined in Fig. 1 . Square arrays of vertically grown ZnO NRs were prepared as described in our previous studies [28] [29] [30] [31] and further employed directly after their synthesis as the patient cytokine and chemokine detection platforms. The crystal and chemical structures of the as-grown nanomaterials were reported previously along with their X-ray diffraction and photoluminescence data. 44, 45 In short, the patterned ZnO NR ensembles were obtained by localizing catalysts only to predetermined locations of the growth substrate via microcontact printing. An optical micrograph of a typical ZnO NR square array produced via the microcontact-printed catalyst delivery method is shown Page 9 of 29 Nanoscale 10 in Fig. 1(A) , presenting a 0.5 x 0.5 mm 2 view frame of the ZnO NR patches. The ZnO NR arrays used in our bioassays contain square blocks of 10 µm in length spaced 10 µm apart. With no post-synthetic modifications, the ZnO NR arrays were employed to carry out the sandwich protein assay, whose key biomedical procedures are depicted step by step in Fig. 1(B) . The typical diameters and lengths of the NRs employed in our measurements range from 150 to 300 nm and from 5 to 10 µm, respectively, depending on the array plates. The chosen NR size ranges are known to couple and guide visible light 46, 47 and Alexa 546. Representative emission data are qualitatively presented in Fig. 2(A) . The TNF-α (left) and IL-8 (right) fluorescence images were obtained from the same assay to demonstrate the multiplexing capability of the platform. As a direct comparison, the panels in Fig. 2 assessed by repeating the cytokine and chemokine measurements for two selected patients (17 and 19) .
Page 8 of 29 Nanoscale

Nanoscale Accepted Manuscript
For each of these patients, the ZnO NRs-based assays were repeated five times on the same NR plate, and the average fluorescence intensities obtained from these five independent runs per patient are shown in the bar graph sets indicated with ** in Fig. 2(D) . In addition, the potential variability in the biomarker detection due to ZnO NR array-to-array differences was also evaluated by assaying the same samples on three different ZnO NR plates. The results are displayed in the paired bar graphs marked with * in Fig. 2(D) . The inter-assay (the assessment of ZnO NR plate-to-plate consistency) coefficients of variation for TNF-α and IL-8 were 12 and 2.8 % while the intra-assay (the assessment from repeated measurements on the same ZnO NR plate) coefficients of variation were 16.5 and 2.5 %. Both are below the generally accepted value of 10-20%. 48
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To assess the effectiveness of our ZnO NRs-based approach in simultaneously detecting the levels of TNF-α and IL-8 in patient urine samples, the concentrations obtained from the ZnO NR sandwich assays were compared directly to those determined in the same patient samples using commercially available ELISA kits. In order to make quantitative comparisons, calibration curves were generated for each protein using standard solutions containing known amounts of IL-8 and TNF-α. Fig. 4(A) display the patient IL-8 levels from the two techniques based on their respective calibration curves in Fig. 3 . Urine IL-8 could be detected in all of the individuals with either the ELISA-or ZnO NRs-based method and ranged between several tens of pg/mL to a few ng/mL. The bar graphs in Fig. 4(B) , plotted using an upper limit of 400 pg/mL, more clearly illustrate the agreement between the two methods for samples with lower IL-8 levels. For additional quantitative comparison between the IL-8 results acquired by the ELISA and ZnO NR approaches, the readings were evaluated using the Bland-Altman analysis. 53 The results from the analysis are summarized in Fig. 5 . The correlative plot in Fig. 5(A) displays the IL-8 readings from the same patients determined by the ELISA and ZnO NRs method on the x and y axis, respectively, as well as the linear fit of the data points shown as the dashed red line. The solid black line, signifying identical IL-8 readings from the two methods, is superimposed on the scatter plot as a guide to the eye. Our data points lie on or close to the guide line, indicating excellent agreement between the IL-8 values established by the two assay techniques. Additionally, the histogram distribution chart in Fig. 5(B) shows the number of samples exhibiting the various differences between the IL-8 concentrations using Page 16 of 29 Nanoscale each assay method. The majority of the IL-8 readings from the two methods fell within the range of ±2.5 pg/mL. The IL-8 concentrations obtained from the two methods were also compared by plotting the differences between the ELISA and ZnO NR readings versus the mean concentration values between the two techniques. The analyzed data centered near the black lines inserted in Figs. 5(C and D) whose traces represent equivalent IL-8 readings from the same patient when assayed by the two methods.
Hence, based on these comparative IL-8 results, we demonstrate that the ZnO NR platform can be successfully employed for the accurate quantification of urinary biomarker proteins directly from patient samples. suggests that the potential application of our ZnO NRs-based approach is not limited just to serving as an alternative or a tandem detection platform to an existing measurement method, but rather, its role can be extended to the much needed, ultrasensitive detection of biomarker proteins in samples below the concentration levels that standard techniques can ascertain. Fig. 7 . The majority of these levels were below the DL of the ELISA assay. The data presented in Fig. 7 suggest that the typical range of the urine TNF-α concentrations in the no AKI group is below several hundreds of fg/mL whereas the TNF-α levels of the majority of patients associated with the Day 1 AKI group lie above a few pg/mL. The data from the patients in the ICU AKI category separate into two concentration blocks, one close to that of the no AKI and the other similar to that of the Day 1 AKI patients. Hence, the ZnO NR method may enable diagnostic or predictive use of urine TNF-α levels for clinical use by providing information that cannot be facilely deduced from conventional, lower sensitivity assays. The typical concentrations of IL-8 and TNF-α in healthy subjects are reported to be approximately in the range of 40 pg/mL and 5 pg/mL, respectively, in a study involving human serum samples. 54 In another study involving urine samples, the control (no AKI) group showed IL-8 and TNF-α levels of 1.5 pg/mL and 0.12 pg/mL, respectively, whereas these values changed significantly to 74 pg/mL and 14 pg/mL, respectively, for the test (AKI) group. 55 While these values are provided as a point of reference, it should be also noted that various factors such as the age, gender, ethnicity, simultaneous occurring health problems, and dates of sample collection can all affect the exact baseline levels of the proteins.
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Summary
In summary, we have demonstrated that ZnO NRs can be successfully employed in the rapid, ultrasensitive, quantitative, and simultaneous detection of multiple AKI-related biomarkers in patient urine. Using the model protein of IL-8 for an AKI-implicated chemokine, we validated and benchmarked the detection readouts and the performance parameters of our ZnO NRs-based fluorescence technique against a conventional ELISA-based method on the same patient samples. We further evaluated the full detection capability of the ZnO NRs-based technique by quantifying the amounts of another AKI-related cytokine, TNF-α, whose levels in urine are often below the DLs of conventional detection methods. We first established the DLs of the ZnO NRs-based platform to be in the several fg/mL range. We subsequently employed the technique for the reliable and repeated quantification of the low-expressed, hard-to-trace TNF-α concentrations in patient urine samples. We have also demonstrated the feasibility of using our ZnO NRs-based approach for differentiating cytokine concentration ranges in different patient groups and for serving as a potential guide for further clinical monitoring. The fact that the ultrahigh detection sensitivity can be conveniently and straightforwardly achieved from minimally processed patient samples suggests potentially exciting and useful applications of the presented ZnO NRs-based assay schemes both in basic biology research and clinical studies for early disease diagnosis and treatments. In conjunction with the other advantages of our ZnO NRs-based detection approach as detailed in the discussion section, its application may be readily extended to other biomarker systems in physiological samples, beyond the model proteins in this study.
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